|
DK3243526T3
(da)
|
2010-07-06 |
2020-02-17 |
Glaxosmithkline Biologicals Sa |
Levering af rna til at udløse flere immunsignalveje
|
|
JP2013537518A
(ja)
|
2010-07-06 |
2013-10-03 |
ノバルティス アーゲー |
ＲＮＡ送達に有利なｐＫａ値を有する脂質を含むリポソーム
|
|
CA2804492A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
|
FI4043040T3
(fi)
|
2010-08-31 |
2023-04-04 |
Glaxosmithkline Biologicals Sa |
Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi
|
|
FI4066857T3
(fi)
|
2010-08-31 |
2023-03-20 |
Glaxosmithkline Biologicals Sa |
Pegyloituja liposomeja immunogeeniä koodaavan rna:n kuljettamiseksi
|
|
RU2597974C2
(ru)
|
2010-10-11 |
2016-09-20 |
Новартис Аг |
Платформы доставки антигенов
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
EP4074693A1
(en)
|
2011-06-08 |
2022-10-19 |
Translate Bio, Inc. |
Cleavable lipids
|
|
WO2013006838A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
LT4023249T
(lt)
|
2014-04-23 |
2025-01-10 |
Modernatx, Inc. |
Nuleorūgšties vakcinos
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
US10653768B2
(en)
|
2015-04-13 |
2020-05-19 |
Curevac Real Estate Gmbh |
Method for producing RNA compositions
|
|
EP3289083A4
(en)
*
|
2015-04-27 |
2018-12-19 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
ES2984981T3
(es)
|
2015-06-29 |
2024-10-31 |
Acuitas Therapeutics Inc |
Lípidos y formulaciones de nanopartículas lipídicas para el suministro de ácidos nucleicos
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
MA42543A
(fr)
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
EA037478B1
(ru)
|
2015-08-04 |
2021-04-01 |
Дьюк Юниверсити |
Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
|
|
ES2910425T3
(es)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
DE20164728T1
(de)
|
2015-10-22 |
2021-09-30 |
Modernatx, Inc. |
Impfstoffe gegen atemwegsvirus
|
|
SI3368507T1
(sl)
|
2015-10-28 |
2023-04-28 |
Acuitas Therapeutics Inc. |
Novi lipidi in formulacije lipidnih nanodelcev za dostavo nukleinskih kislin
|
|
WO2017099823A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
|
EP3390630B1
(en)
|
2015-12-17 |
2025-01-22 |
ModernaTX, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
DK3394030T3
(da)
|
2015-12-22 |
2022-03-28 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af midler
|
|
WO2017201332A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
|
US20200085916A1
(en)
*
|
2016-05-18 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
|
EP3458108A4
(en)
|
2016-05-18 |
2020-04-22 |
ModernaTX, Inc. |
POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
AU2017268394A1
(en)
|
2016-05-18 |
2019-01-03 |
Modernatx, Inc. |
Polynucleotides encoding relaxin
|
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
WO2017201349A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
WO2017201333A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
|
|
US20190382774A1
(en)
*
|
2016-05-18 |
2019-12-19 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
US11467156B2
(en)
|
2016-06-01 |
2022-10-11 |
Duke University |
Nonfouling biosensors
|
|
CN110023326A
(zh)
|
2016-09-23 |
2019-07-16 |
杜克大学 |
具有lcst行为的非结构化无重复多肽
|
|
ES3047063T3
(en)
|
2016-10-20 |
2025-12-03 |
Sangamo Therapeutics Inc |
Methods and compositions for the treatment of fabry disease
|
|
CA3041307A1
(en)
|
2016-10-21 |
2018-04-26 |
Giuseppe Ciaramella |
Human cytomegalovirus vaccine
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
RU2765874C2
(ru)
|
2016-10-26 |
2022-02-04 |
МОДЕРНАТиЭкс, ИНК. |
Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
|
|
IL266194B2
(en)
*
|
2016-10-26 |
2023-09-01 |
Curevac Ag |
mRNA vaccines with lipid nanoparticles
|
|
US20190274968A1
(en)
*
|
2016-10-27 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
CA3039137A1
(en)
|
2016-11-08 |
2018-05-17 |
Ramot At Tel-Aviv University Ltd. |
Cationic lipids for nucleic acid delivery and preparation thereof
|
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US10925958B2
(en)
|
2016-11-11 |
2021-02-23 |
Modernatx, Inc. |
Influenza vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
EP3558354A1
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Lassa virus vaccine
|
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
|
SG11201906392WA
(en)
|
2017-01-11 |
2019-08-27 |
Univ Pennsylvania |
Nucleoside-modified rna for inducing an immune response against zika virus
|
|
US11648200B2
(en)
|
2017-01-12 |
2023-05-16 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
KR20190110612A
(ko)
|
2017-02-01 |
2019-09-30 |
모더나티엑스, 인크. |
활성화 종양유전자 돌연변이 펩티드를 인코드하는 면역조절 치료 mrna 조성물
|
|
EP3609534A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
WIDE SPECTRUM INFLUENZA VIRUS VACCINE
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
LT3596041T
(lt)
|
2017-03-15 |
2023-01-25 |
Modernatx, Inc. |
Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
|
|
US11203569B2
(en)
|
2017-03-15 |
2021-12-21 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
WO2019012336A2
(en)
|
2017-03-17 |
2019-01-17 |
Newcastle University |
ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY
|
|
CA3050616A1
(en)
|
2017-03-24 |
2018-09-27 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US11596679B2
(en)
|
2017-04-27 |
2023-03-07 |
Vanderbilt University |
Hepatitis C virus gene sequences and methods of use therefor
|
|
CA3061612A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
EP3624824B1
(en)
|
2017-05-16 |
2024-07-10 |
Translate Bio, Inc. |
Codon-optimized mrna encoding cftr for use in treating cystic fibrosis
|
|
WO2018225871A1
(ja)
*
|
2017-06-09 |
2018-12-13 |
協和発酵キリン株式会社 |
カチオン性脂質としての化合物
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3641834B1
(en)
|
2017-06-19 |
2023-10-04 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
|
EP3658168A4
(en)
|
2017-06-30 |
2021-07-14 |
Duke University |
ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
|
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
JP7461872B2
(ja)
*
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
|
WO2019126593A1
(en)
|
2017-12-20 |
2019-06-27 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
EP3733211A4
(en)
|
2017-12-27 |
2021-11-24 |
Takeda Pharmaceutical Company Limited |
LIPID NANOPARTICLE CONTAINING NUCLEIC ACID AND USE OF THE SAME
|
|
WO2019147954A1
(en)
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
|
JP2021512090A
(ja)
|
2018-01-30 |
2021-05-13 |
モデルナティーエックス， インコーポレイテッド |
免疫細胞に薬剤を送達するための組成物及び方法
|
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
US20210170017A1
(en)
|
2018-04-17 |
2021-06-10 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
US12257308B2
(en)
|
2018-04-30 |
2025-03-25 |
Duke University |
Stimuli-responsive PEG-like polymer-based drug delivery platform
|
|
US20210220449A1
(en)
|
2018-05-15 |
2021-07-22 |
Translate Bio, Inc. |
Subcutaneous Delivery of Messenger RNA
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
CN112437767B
(zh)
*
|
2018-05-24 |
2023-10-27 |
川斯勒佰尔公司 |
硫酯阳离子脂质
|
|
JP7463006B2
(ja)
|
2018-05-30 |
2024-04-08 |
トランスレイト バイオ， インコーポレイテッド |
ステロイド性部分を含むカチオン性脂質
|
|
WO2019232095A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
|
CN112672761A
(zh)
|
2018-05-30 |
2021-04-16 |
川斯勒佰尔公司 |
磷酸酯阳离子脂质
|
|
CN118436618A
(zh)
|
2018-05-30 |
2024-08-06 |
川斯勒佰尔公司 |
信使rna疫苗及其用途
|
|
FI3807413T3
(fi)
|
2018-06-18 |
2025-08-13 |
Res Inst Nationwide Childrens Hospital |
Lihasspesifisen mikrodystrofiinin annostelu adeno-assosioituneella virusvektorilla lihasdystrofian hoitamiseksi
|
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
JP7422977B2
(ja)
|
2018-07-23 |
2024-01-29 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａ用乾燥粉末製剤
|
|
EP3829622A4
(en)
|
2018-08-02 |
2022-05-11 |
Duke University |
DOUBLE AGONIST FUSION PROTEINS
|
|
CN112839639A
(zh)
|
2018-08-29 |
2021-05-25 |
川斯勒佰尔公司 |
制备负载mRNA的脂质纳米颗粒的改进方法
|
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
CA3112781A1
(en)
|
2018-09-14 |
2020-03-19 |
Modernatx, Inc. |
Methods and compositions for treating cancer using mrna therapeutics
|
|
EP3853202A1
(en)
*
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CN112996854B
(zh)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
高纯度peg脂质和其用途
|
|
CA3113449A1
(en)
|
2018-09-21 |
2020-03-26 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
KR20210092717A
(ko)
|
2018-10-01 |
2021-07-26 |
요하네스 구텐베르크-유니버시타트 마인츠 |
폴리사르코신을 포함하는 rna 입자
|
|
SG11202102921WA
(en)
*
|
2018-10-02 |
2021-04-29 |
Intellia Therapeutics Inc |
Ionizable amine lipids
|
|
AU2019361129A1
(en)
*
|
2018-10-18 |
2021-05-20 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
BR112021007360A2
(pt)
|
2018-10-18 |
2021-07-20 |
Takeda Pharmaceutical Company Limited |
métodos para ativar/proliferar células t, para distribuir um ácido nucleico em células t e para produzir um medicamento, célula t, medicamento, cultura de células, composição, e, kit para distribuir um ácido nucleico em células t
|
|
AU2019362031A1
(en)
|
2018-10-19 |
2021-04-08 |
Translate Bio, Inc. |
Pumpless encapsulation of messenger RNA
|
|
EP3877444A1
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
CN113272282B
(zh)
|
2018-11-09 |
2024-11-08 |
川斯勒佰尔公司 |
具有插入的酯、硫酯、二硫化物和酸酐部分的2,5-二氧代哌嗪脂质
|
|
CA3117877A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
EP3876914A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
AU2019378763B2
(en)
|
2018-11-12 |
2025-06-26 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
|
EP3883917B1
(en)
|
2018-11-21 |
2024-01-24 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
CA3118034A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Rna for malaria vaccines
|
|
CA3125588A1
(en)
|
2019-01-07 |
2020-07-16 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
FI3908568T3
(fi)
|
2019-01-11 |
2024-09-13 |
Acuitas Therapeutics Inc |
Lipidit aktiivisten aineiden lipidinanohiukkastoimitusta varten
|
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
US20220177423A1
(en)
|
2019-04-18 |
2022-06-09 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
ES2972014T3
(es)
|
2019-04-22 |
2024-06-10 |
Translate Bio Inc |
Lípidos catiónicos de tioéster
|
|
EP3962902A1
(en)
*
|
2019-05-03 |
2022-03-09 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
MA55896A
(fr)
|
2019-05-07 |
2022-03-16 |
Modernatx Inc |
Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser
|
|
WO2020227537A1
(en)
|
2019-05-07 |
2020-11-12 |
Modernatx, Inc |
Differentially expressed immune cell micrornas for regulation of protein expression
|
|
KR20220027855A
(ko)
|
2019-05-22 |
2022-03-08 |
매사추세츠 인스티튜트 오브 테크놀로지 |
원형 rna 조성물 및 방법
|
|
US20220226244A1
(en)
|
2019-05-31 |
2022-07-21 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
WO2020247882A1
(en)
|
2019-06-07 |
2020-12-10 |
Scribe Therapeutics Inc. |
Engineered casx systems
|
|
CN114340664A
(zh)
|
2019-06-18 |
2022-04-12 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
|
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
WO2020255014A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Recombinant interleukin 12 construct and uses thereof
|
|
US20220296703A1
(en)
|
2019-06-18 |
2022-09-22 |
Janssen Sciences Ireland Unlimited Company |
Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
US20220313813A1
(en)
|
2019-06-18 |
2022-10-06 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
MA56536A
(fr)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)
|
|
WO2020257716A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
EP4467653B1
(en)
|
2019-07-08 |
2026-01-21 |
Translate Bio, Inc. |
Improved mrna-loaded lipid nanoparticles and processes of making the same
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
CN114423869A
(zh)
|
2019-07-19 |
2022-04-29 |
旗舰先锋创新Vi有限责任公司 |
重组酶组合物和使用方法
|
|
KR20220038365A
(ko)
|
2019-07-23 |
2022-03-28 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자의 안정한 조성물 및 제조 방법
|
|
JP7769325B2
(ja)
|
2019-07-23 |
2025-11-13 |
株式会社東芝 |
Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
|
|
EP4003296A1
(en)
|
2019-07-31 |
2022-06-01 |
ModernaTX, Inc. |
Compositions and methods for delivery of rna interference agents to immune cells
|
|
US20220296517A1
(en)
|
2019-08-07 |
2022-09-22 |
Moderna TX, Inc. |
Compositions and methods for enhanced delivery of agents
|
|
CA3144902A1
(en)
|
2019-08-14 |
2022-01-19 |
Andreas Thess |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
JP7753190B2
(ja)
|
2019-08-14 |
2025-10-14 |
アクイタス セラピューティクス インコーポレイテッド |
核酸の送達のための改善された脂質ナノ粒子
|
|
US20220280427A1
(en)
|
2019-09-06 |
2022-09-08 |
Generation Bio Co. |
Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof
|
|
BR112022004759A2
(pt)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
|
|
AU2020351220A1
(en)
*
|
2019-09-19 |
2022-04-07 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
JP2022548320A
(ja)
|
2019-09-23 |
2022-11-17 |
オメガ セラピューティクス， インコーポレイテッド |
アポリポタンパク質ｂ（ａｐｏｂ）遺伝子発現をモジュレートするための組成物および方法
|
|
AU2020352552A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
|
JP2022552371A
(ja)
|
2019-10-15 |
2022-12-15 |
モデルナティエックス インコーポレイテッド |
免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用
|
|
WO2021081058A1
(en)
|
2019-10-21 |
2021-04-29 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
US20220370357A1
(en)
|
2019-11-22 |
2022-11-24 |
Generation Bio Co. |
Ionizable lipids and nanoparticle compositions thereof
|
|
EP3920976B1
(en)
|
2019-12-04 |
2023-07-19 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2021127394A2
(en)
|
2019-12-20 |
2021-06-24 |
Translate Bio, Inc. |
Rectal delivery of messenger rna
|
|
CA3165388A1
(en)
|
2019-12-20 |
2021-06-24 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
EP4103542A4
(en)
|
2020-01-09 |
2024-02-14 |
Guide Therapeutics, LLC |
NANOMATERIALS
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
JP2023510308A
(ja)
|
2020-01-10 |
2023-03-13 |
モデルナティエックス インコーポレイテッド |
寛容原性樹状細胞を作る方法
|
|
CA3168945A1
(en)
|
2020-01-30 |
2021-08-05 |
Modernatx, Inc. |
Mrnas encoding metabolic reprogramming polypeptides and uses thereof
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
TW202140518A
(zh)
|
2020-02-04 |
2021-11-01 |
德商奎爾法克股份有限公司 |
冠狀病毒疫苗
|
|
EP4110296A1
(en)
|
2020-02-25 |
2023-01-04 |
Translate Bio, Inc. |
Improved processes of preparing mrna-loaded lipid nanoparticles
|
|
IL296234A
(en)
*
|
2020-03-11 |
2022-11-01 |
Advansix Resins & Chemicals Llc |
Surfactants for healthcare products
|
|
EP4118207A1
(en)
|
2020-03-11 |
2023-01-18 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
EP4118164A1
(en)
|
2020-03-11 |
2023-01-18 |
AdvanSix Resins & Chemicals LLC |
Surfactants for oil and gas production
|
|
CA3172423A1
(en)
|
2020-03-20 |
2021-03-22 |
Alex WESSELHOEFT |
Circular rna compositions and methods
|
|
AU2021244555A1
(en)
|
2020-03-24 |
2022-11-24 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
WO2021195218A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
WO2021195529A2
(en)
|
2020-03-27 |
2021-09-30 |
Generation Bio Co. |
Novel lipids and nanoparticle compositions thereof
|
|
CA3174588A1
(en)
|
2020-03-30 |
2021-10-07 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
FI20215508A1
(en)
|
2020-04-09 |
2021-10-10 |
Niemelae Erik Johan |
Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
|
|
KR20230016175A
(ko)
|
2020-04-09 |
2023-02-01 |
버브 테라퓨틱스, 인크. |
Angptl3의 염기 편집 및 질환 치료를 위한 이의 사용 방법
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
US12023376B1
(en)
|
2020-04-17 |
2024-07-02 |
Triad National Security, Llc |
Conserved region T cell vaccines for coronavirus and methods of use
|
|
KR102813425B1
(ko)
|
2020-04-22 |
2025-05-28 |
바이오엔테크 에스이 |
코로나바이러스 백신
|
|
IL297962A
(en)
|
2020-05-07 |
2023-01-01 |
Translate Bio Inc |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
|
US20230181619A1
(en)
|
2020-05-07 |
2023-06-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
US20230190954A1
(en)
|
2020-05-07 |
2023-06-22 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
WO2021231697A1
(en)
|
2020-05-14 |
2021-11-18 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
WO2021231901A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
MX2022014660A
(es)
|
2020-05-19 |
2023-02-16 |
Orna Therapeutics Inc |
Composiciones y métodos de arn circular.
|
|
WO2021236930A1
(en)
|
2020-05-20 |
2021-11-25 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
EP4153224A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus antigen compositions and their uses
|
|
EP4158031A1
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
MX2022015132A
(es)
|
2020-05-29 |
2023-03-08 |
CureVac SE |
Vacunas combinadas a base de acidos nucleicos.
|
|
CA3182026A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
IL299094A
(en)
|
2020-06-15 |
2023-02-01 |
Res Inst Nationwide Childrens Hospital |
Administration of an adeno-associated virus vector for muscular dystrophies
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2022006527A1
(en)
|
2020-07-02 |
2022-01-06 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
WO2022008613A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
IL299787A
(en)
|
2020-07-16 |
2023-03-01 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
AU2021314809A1
(en)
|
2020-07-27 |
2023-02-23 |
Anjarium Biosciences Ag |
Compositions of DNA molecules, methods of making therefor, and methods of use thereof
|
|
CA3170741A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
AU2021320426A1
(en)
|
2020-08-06 |
2023-03-23 |
Modernatx, Inc. |
Compositions for the delivery of payload molecules to airway epithelium
|
|
CN114073677B
(zh)
*
|
2020-08-20 |
2023-06-09 |
深圳深信生物科技有限公司 |
一种脂质纳米颗粒
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
CA3193746A1
(en)
|
2020-09-03 |
2022-03-10 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
US20230372440A1
(en)
|
2020-10-06 |
2023-11-23 |
Translate Bio, Inc. |
Improved process and formulation of lipid nanoparticles
|
|
AU2021361986A1
(en)
|
2020-10-12 |
2023-06-15 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
WO2022081752A1
(en)
*
|
2020-10-14 |
2022-04-21 |
George Mason Research Foundation, Inc. |
Methods of lipid nanoparticle manufacture and compostions derived therefrom
|
|
JP2023548587A
(ja)
|
2020-11-09 |
2023-11-17 |
トランスレイト バイオ， インコーポレイテッド |
コドン最適化したｍＲＮＡの送達のための改善された組成物
|
|
WO2022218503A1
(en)
*
|
2021-04-12 |
2022-10-20 |
BioNTech SE |
Lnp compositions comprising rna and methods for preparing, storing and using the same
|
|
CA3198742A1
(en)
*
|
2020-11-16 |
2022-05-19 |
Steffen Panzner |
Lnp compositions comprising rna and methods for preparing, storing and using the same
|
|
AU2021376893A1
(en)
*
|
2020-11-16 |
2023-06-15 |
BioNTech SE |
Enhanced formulation stabilization and improved lyophilization processes
|
|
US20240041785A1
(en)
|
2020-11-16 |
2024-02-08 |
BioNTech SE |
Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
|
|
CA3198309A1
(en)
*
|
2020-11-16 |
2022-05-19 |
Heinrich Haas |
Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same
|
|
CN116669709A
(zh)
*
|
2020-11-16 |
2023-08-29 |
生物技术公司 |
包含颗粒和mRNA的药物组合物及其制备和储存的方法
|
|
US11421015B2
(en)
|
2020-12-07 |
2022-08-23 |
Think Therapeutics, Inc. |
Method of compact peptide vaccines using residue optimization
|
|
CN116710115A
(zh)
|
2020-11-20 |
2023-09-05 |
思维疗法股份有限公司 |
用于优化的肽疫苗的组合物和方法
|
|
US11058751B1
(en)
|
2020-11-20 |
2021-07-13 |
Think Therapeutics, Inc. |
Compositions for optimized RAS peptide vaccines
|
|
AU2021386737A1
(en)
|
2020-11-25 |
2023-07-13 |
Translate Bio, Inc. |
Stable liquid lipid nanoparticle formulations
|
|
WO2022112855A1
(en)
*
|
2020-11-27 |
2022-06-02 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
|
CN113185421B
(zh)
*
|
2020-11-27 |
2022-01-25 |
广州市锐博生物科技有限公司 |
脂质化合物及其组合物
|
|
EP4025556A4
(en)
*
|
2020-11-27 |
2023-08-09 |
Guangzhou Ribobio Co., Ltd |
LIPID COMPOUND AND ITS COMPOSITION
|
|
JP2023552374A
(ja)
|
2020-12-03 |
2023-12-15 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたクラス２ ｖ型ｃｒｉｓｐｒシステム
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
US20240299309A1
(en)
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
EP4267732A1
(en)
|
2020-12-23 |
2023-11-01 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
US20240316090A1
(en)
|
2020-12-28 |
2024-09-26 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
WO2022152109A2
(en)
*
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
KR20230121616A
(ko)
*
|
2021-01-14 |
2023-08-18 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
지질 화합물 및 지질 나노입자 조성물
|
|
CN116981692A
(zh)
|
2021-01-14 |
2023-10-31 |
翻译生物公司 |
递送mRNA编码的抗体的方法和组合物
|
|
US20240317939A1
(en)
*
|
2021-01-15 |
2024-09-26 |
Pfizer Inc. |
Methods for producing of lipids
|
|
US12268753B2
(en)
|
2021-01-20 |
2025-04-08 |
Beam Therapeutics Inc. |
Nanomaterials comprising a biodegradable feature
|
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
CN112961091B
(zh)
*
|
2021-02-07 |
2022-06-17 |
深圳深信生物科技有限公司 |
一种氨基脂质化合物及其制备方法和用途
|
|
WO2022166747A1
(zh)
*
|
2021-02-07 |
2022-08-11 |
深圳深信生物科技有限公司 |
一种氨基脂质化合物及其制备方法和用途
|
|
US20240123076A1
(en)
|
2021-02-08 |
2024-04-18 |
The Board Of Regents Of The University Of Texas System |
Unsaturated dendrimers compositions, related formulations, and methods of use thereof
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
US20240207178A1
(en)
|
2021-03-22 |
2024-06-27 |
Recode Therapeutics, Inc. |
Compositions and methods for targeted delivery to cells
|
|
KR20230175196A
(ko)
|
2021-03-23 |
2023-12-29 |
리코드 테라퓨틱스, 인크. |
폴리뉴클레오티드 조성물, 관련된 제제, 및 이의 사용 방법
|
|
EP4313894A1
(en)
|
2021-03-25 |
2024-02-07 |
SCHOTT Pharma AG & Co. KGaA |
Pharmaceutical container
|
|
EP4313115A1
(en)
|
2021-03-25 |
2024-02-07 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
|
WO2022200575A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4314332A2
(en)
|
2021-04-01 |
2024-02-07 |
ModernaTX, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
|
EP4319803B1
(en)
|
2021-04-08 |
2025-11-26 |
Vaxthera SAS |
Coronavirus vaccine comprising a mosaic protein
|
|
CN115515926B
(zh)
*
|
2021-04-08 |
2023-10-20 |
厦门赛诺邦格生物科技股份有限公司 |
一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
|
|
CN115197078B
(zh)
*
|
2021-04-08 |
2024-06-04 |
厦门赛诺邦格生物科技股份有限公司 |
一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
|
|
JP2024518689A
(ja)
*
|
2021-04-09 |
2024-05-02 |
ファイザー・インク |
脂質を生産するための方法
|
|
WO2022218891A2
(en)
|
2021-04-12 |
2022-10-20 |
BioNTech SE |
Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
|
|
ES2995558T3
(en)
*
|
2021-04-13 |
2025-02-10 |
Westgene Biopharma Co Ltd |
Ionizable lipids and compositions for nucleic acid delivery
|
|
CA3215606A1
(en)
|
2021-04-19 |
2022-10-27 |
Shrirang KARVE |
Improved compositions for delivery of mrna
|
|
CA3214538A1
(en)
|
2021-04-20 |
2022-10-27 |
Joel DE BEER |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
US20240226324A1
(en)
|
2021-04-27 |
2024-07-11 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
US11464842B1
(en)
|
2021-04-28 |
2022-10-11 |
Think Therapeutics, Inc. |
Compositions and method for optimized peptide vaccines using residue optimization
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
AU2022270658A1
(en)
|
2021-05-04 |
2023-11-16 |
BioNTech SE |
Technologies for early detection of variants of interest
|
|
AU2022281746B2
(en)
*
|
2021-05-24 |
2025-01-16 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
WO2022251665A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles and methods of use thereof
|
|
AU2022288705A1
(en)
|
2021-06-10 |
2023-12-07 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
CA3222589A1
(en)
|
2021-06-14 |
2022-12-22 |
Matthew G. Stanton |
Cationic lipids and compositions thereof
|
|
EP4183770A1
(en)
|
2021-11-22 |
2023-05-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Continuous flow process for production of cationic lipids
|
|
CA3224056A1
(en)
|
2021-06-24 |
2022-12-29 |
Peter Seeberger |
Continuous flow process for production of cationic lipids
|
|
WO2023278754A1
(en)
|
2021-07-01 |
2023-01-05 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
EP4370551A1
(en)
|
2021-07-15 |
2024-05-22 |
BioNTech SE |
Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
|
|
CN113264842B
(zh)
*
|
2021-07-21 |
2022-03-01 |
苏州科锐迈德生物医药科技有限公司 |
一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
TW202320842A
(zh)
|
2021-07-29 |
2023-06-01 |
德商拜恩技術股份公司 |
用於治療黑色素瘤之組合物及方法
|
|
WO2023006999A2
(en)
|
2021-07-30 |
2023-02-02 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
|
US20240325308A1
(en)
*
|
2021-08-04 |
2024-10-03 |
The Trustees Of The University Of Pennsylvania |
Amniotic fluid stabilized compositions and methods for in utero delivery of therapeutic agents
|
|
EP4381084A1
(en)
|
2021-08-04 |
2024-06-12 |
Modernatx, Inc. |
Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
|
|
CN115703713B
(zh)
*
|
2021-08-13 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115703714B
(zh)
*
|
2021-08-13 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
CN115710192B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115710191B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115710193B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
EP4141013A1
(en)
|
2021-08-31 |
2023-03-01 |
Studiengesellschaft Kohle mbH |
Stereochemically pure lipids for nucleic acid delivery
|
|
WO2023030635A1
(en)
|
2021-09-02 |
2023-03-09 |
BioNTech SE |
Potency assay for therapeutic potential of coding nucleic acid
|
|
JP2024538489A
(ja)
|
2021-09-03 |
2024-10-23 |
キュアバック エスイー |
核酸を送達するための新規な脂質ナノ粒子
|
|
CN118043466A
(zh)
|
2021-09-03 |
2024-05-14 |
葛兰素史克生物有限公司 |
自扩增信使核糖核酸中核苷酸碱基的取代
|
|
WO2023031392A2
(en)
|
2021-09-03 |
2023-03-09 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
CN115745819B
(zh)
*
|
2021-09-03 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
JP2024534697A
(ja)
|
2021-09-14 |
2024-09-20 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
非環状脂質及びその使用方法
|
|
JP2024533865A
(ja)
|
2021-09-14 |
2024-09-12 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
環状脂質及びその使用方法
|
|
KR20240099185A
(ko)
|
2021-09-17 |
2024-06-28 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
원형 폴리리보뉴클레오티드를 생성하기 위한 조성물 및 방법
|
|
CA3233243A1
(en)
|
2021-09-30 |
2023-04-06 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
AR127312A1
(es)
*
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
EP4412646A1
(en)
|
2021-10-08 |
2024-08-14 |
Pfizer Inc. |
Immunogenic lnp compositions and methods thereof
|
|
WO2023064469A1
(en)
|
2021-10-13 |
2023-04-20 |
Modernatx, Inc. |
Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
|
|
TW202327646A
(zh)
|
2021-10-15 |
2023-07-16 |
美商輝瑞大藥廠 |
Rna分子
|
|
JP2024538144A
(ja)
|
2021-10-18 |
2024-10-18 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
ポリリボヌクレオチドを精製するための組成物及び方法
|
|
EP4238577A3
(en)
|
2021-10-22 |
2023-12-06 |
BioNTech SE |
Compositions for administration of different doses of rna
|
|
JP2024539512A
(ja)
|
2021-10-22 |
2024-10-28 |
セイル バイオメディシンズ インコーポレイテッド |
Ｍｒｎａワクチン組成物
|
|
WO2023073228A1
(en)
|
2021-10-29 |
2023-05-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
JP2024540170A
(ja)
|
2021-11-01 |
2024-10-31 |
モデルナティエックス インコーポレイテッド |
インテグリンベータ－６をコードするポリヌクレオチド及びその使用方法
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
CA3236235A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2023083434A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
|
|
JP2024545572A
(ja)
|
2021-11-10 |
2024-12-10 |
トランスレイト バイオ， インコーポレイテッド |
原発性線毛機能不全の治療のための組成物及び方法
|
|
WO2023086465A1
(en)
|
2021-11-12 |
2023-05-19 |
Modernatx, Inc. |
Compositions for the delivery of payload molecules to airway epithelium
|
|
CA3238292A1
(en)
|
2021-11-16 |
2023-05-25 |
Alessandra Bartolozzi |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
MX2024006134A
(es)
|
2021-11-22 |
2024-07-29 |
Sail Biomedicines Inc |
Lipidos ionizables novedosos y nanoparticulas de lipido y metodos para usar los mismos.
|
|
US20250002941A1
(en)
|
2021-11-23 |
2025-01-02 |
Sail Biomedicines, Inc. |
A bacteria-derived lipid composition and use thereof
|
|
EP4436984A1
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus immunogen compositions and their uses
|
|
KR20240125931A
(ko)
|
2021-11-24 |
2024-08-20 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
수두-대상포진 바이러스 면역원 조성물 및 이의 용도
|
|
JP2024541465A
(ja)
|
2021-11-24 |
2024-11-08 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
免疫原性組成物及びその使用
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
AR127892A1
(es)
*
|
2021-12-10 |
2024-03-06 |
Modernatx Inc |
Compuestos y composiciones para la administración de agentes terapéuticos
|
|
US12129223B2
(en)
|
2021-12-16 |
2024-10-29 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023115013A1
(en)
|
2021-12-17 |
2023-06-22 |
Flagship Pioneering Innovations Vi, Llc |
Methods for enrichment of circular rna under denaturing conditions
|
|
EP4448002A1
(en)
|
2021-12-17 |
2024-10-23 |
Pfizer Inc. |
Polynucleotide compositions and uses thereof
|
|
JP2025500373A
(ja)
|
2021-12-20 |
2025-01-09 |
セイル バイオメディシンズ インコーポレイテッド |
Ｍｒｎａ治療用組成物
|
|
TW202340461A
(zh)
|
2021-12-22 |
2023-10-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物和方法
|
|
KR20240118881A
(ko)
|
2021-12-23 |
2024-08-05 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드
|
|
CA3241492A1
(en)
*
|
2021-12-23 |
2023-06-29 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compound and lipid nanoparticle composition
|
|
US20230201817A1
(en)
|
2021-12-23 |
2023-06-29 |
Biontech Delivery Technologies Gmbh |
Modular drug production system
|
|
EP4452928A1
(en)
*
|
2021-12-23 |
2024-10-30 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
CN114249662B
(zh)
*
|
2021-12-27 |
2024-06-21 |
硅羿科技（上海）有限公司 |
一种药用脂质体辅料alc-0315的制备方法
|
|
WO2023126053A1
(en)
|
2021-12-28 |
2023-07-06 |
BioNTech SE |
Lipid-based formulations for administration of rna
|
|
US20250064750A1
(en)
*
|
2021-12-29 |
2025-02-27 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Lipid and composition used for delivery
|
|
CN114044741B
(zh)
*
|
2022-01-13 |
2022-04-15 |
北京悦康科创医药科技股份有限公司 |
一种阳离子脂质化合物、包含其的组合物及用途
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023141586A1
(en)
|
2022-01-21 |
2023-07-27 |
Orna Therapeutics, Inc. |
Systemic administration of circular rna polynucleotides encoding muscle proteins or protein complexes
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
CN114409554A
(zh)
*
|
2022-01-27 |
2022-04-29 |
英维沃生物科技(苏州)有限公司 |
一种新型阳离子脂质化合物及其组合物和用途
|
|
IL314324A
(en)
|
2022-01-27 |
2024-09-01 |
BioNTech SE |
Pharmaceutical preparations for administration of herpes simplex virus antigens and related methods
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
WO2023143600A1
(zh)
*
|
2022-01-30 |
2023-08-03 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
|
CN116514672B
(zh)
*
|
2022-01-30 |
2025-06-27 |
康希诺生物股份公司 |
一种用于核酸递送的可电离脂质及其lnp组合物和疫苗
|
|
WO2023143591A1
(zh)
*
|
2022-01-30 |
2023-08-03 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
|
EP4472672A1
(en)
|
2022-02-02 |
2024-12-11 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|
|
WO2023148277A1
(en)
|
2022-02-02 |
2023-08-10 |
BioNTech SE |
Agents and methods for targeted delivery of nucleic acids to cells
|
|
TW202345863A
(zh)
|
2022-02-09 |
2023-12-01 |
美商現代公司 |
黏膜投與方法及調配物
|
|
JP2025507571A
(ja)
|
2022-02-18 |
2025-03-21 |
モデルナティエックス インコーポレイテッド |
チェックポイントがんワクチンをコードするｍＲＮＡ及びその使用
|
|
CA3244621A1
(en)
*
|
2022-02-24 |
2023-08-31 |
Vivasor, Inc. |
NEW IONIZABLE CATIONIC LIPIDS
|
|
CN118804743A
(zh)
*
|
2022-03-04 |
2024-10-18 |
益杰立科(上海)生物科技有限公司 |
靶向递送系统和方法
|
|
CA3245737A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
PRIME-BOOST HETEROLOGICAL VACCINE COMPOSITIONS AND METHODS OF USE
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
CN116813493A
(zh)
*
|
2022-03-21 |
2023-09-29 |
苏州科锐迈德生物医药科技有限公司 |
一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
CN114380724B
(zh)
*
|
2022-03-23 |
2022-05-24 |
深圳市瑞吉生物科技有限公司 |
用于递送核酸的阳离子脂质化合物和组合物及用途
|
|
CN119072464A
(zh)
|
2022-03-25 |
2024-12-03 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及其使用方法
|
|
CN114890907B
(zh)
*
|
2022-03-31 |
2023-10-31 |
荣灿生物医药技术(上海)有限公司 |
一种阳离子脂质化合物及其制备方法和应用
|
|
WO2023193892A1
(en)
*
|
2022-04-05 |
2023-10-12 |
BioNTech SE |
Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
EP4504252A2
(en)
|
2022-04-08 |
2025-02-12 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
US20250250614A1
(en)
|
2022-04-11 |
2025-08-07 |
c/o ModernaTX, Inc. |
Detection of mrna purity in a mixture
|
|
EP4516897A4
(en)
|
2022-04-27 |
2025-11-26 |
Shanghai Regenelead Therapies Co Ltd |
NUCLEIC ACID CONSTRUCTION AND ITS USES
|
|
EP4522743A1
(en)
|
2022-05-09 |
2025-03-19 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods of use for treating proliferative disorders
|
|
CN119487196A
(zh)
|
2022-05-13 |
2025-02-18 |
旗舰创业创新七公司 |
双链dna组合物及相关方法
|
|
JP2025515206A
(ja)
|
2022-05-13 |
2025-05-13 |
上海瑞宏迪医薬有限公司 |
Ｕｔｒを含む核酸構築物及びその使用
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
AU2023268051A1
(en)
|
2022-05-13 |
2025-01-02 |
BioNTech SE |
Rna compositions targeting hiv
|
|
US20250340586A1
(en)
|
2022-05-17 |
2025-11-06 |
Modernatx, Inc. |
Preparation of highly concentrated mrna
|
|
CA3253434A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
RNA COMPOSITIONS FOR THE ADMINISTRATION OF MONKEY POULTRY ANTIGENS AND ASSOCIATED METHODS
|
|
KR20250028547A
(ko)
|
2022-05-25 |
2025-02-28 |
큐어백 에스이 |
대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신
|
|
CA3254087A1
(en)
|
2022-05-27 |
2023-11-30 |
Beam Therapeutics Inc. |
IDENTIFICATION OF NANOPARTICLES FOR PREFERENTIAL TARGETING OF TISSUES OR CELLS
|
|
WO2023232747A1
(en)
|
2022-05-30 |
2023-12-07 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
TW202411426A
(zh)
|
2022-06-02 |
2024-03-16 |
美商斯奎柏治療公司 |
經工程化的２類ｖ型ｃｒｉｓｐｒ系統
|
|
TW202413643A
(zh)
|
2022-06-07 |
2024-04-01 |
美商斯奎柏治療公司 |
用於靶向pcsk9的組合物及方法
|
|
JP2025524360A
(ja)
|
2022-06-07 |
2025-07-30 |
スクライブ・セラピューティクス・インコーポレイテッド |
Ｐｃｓｋ９の標的化のための組成物及び方法
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Compositions of lipid nanoparticles and their uses
|
|
EP4539876A2
(en)
|
2022-06-18 |
2025-04-23 |
GlaxoSmithKline Biologicals S.A. |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
CN114773217B
(zh)
|
2022-06-20 |
2022-10-18 |
深圳市瑞吉生物科技有限公司 |
用于递送核酸的阳离子脂质化合物和组合物及用途
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
AU2023288487A1
(en)
|
2022-06-23 |
2025-01-16 |
Turn Biotechnologies, Inc. |
Lipid structures and compositions comprising same
|
|
US20260007604A1
(en)
|
2022-06-23 |
2026-01-08 |
Pfizer Inc. |
USE OF A SPRAY FREEZE-DRYING PROCESS FOR THE LYOPHILIZATION OF A mRNA-ENCAPSULATING LIPID NANOPARTICLES FORMULATION
|
|
CN114989182B
(zh)
*
|
2022-06-23 |
2023-06-23 |
尧唐(上海)生物科技有限公司 |
脂质化合物、包含其的组合物及应用
|
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
EP4544074A1
(en)
|
2022-06-24 |
2025-04-30 |
ModernaTX, Inc. |
Methods of producing rna
|
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
|
US20260002163A1
(en)
|
2022-07-06 |
2026-01-01 |
Molecular Axiom, Llc |
Compositions and methods for treating pancreatic cancer
|
|
WO2024011033A1
(en)
|
2022-07-07 |
2024-01-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogens and methods for inducing an immune response
|
|
EP4393484A1
(en)
|
2022-07-11 |
2024-07-03 |
Themedium Therapeutics Co., Ltd. |
Composition for organ-specific delivery of nucleic acid
|
|
WO2024012556A1
(zh)
*
|
2022-07-15 |
2024-01-18 |
深圳深信生物科技有限公司 |
一种氨基脂质化合物、其制备方法、组合物和应用
|
|
MA71557A
(fr)
|
2022-07-18 |
2025-05-30 |
Renagade Therapeutics Management Inc. |
Composants d'édition génique, systèmes et procédés d'utilisation
|
|
JP2025528020A
(ja)
|
2022-07-20 |
2025-08-26 |
ビーム セラピューティクス インク． |
トリオールを含むナノ材料
|
|
WO2024030856A2
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
CA3260283A1
(en)
|
2022-08-01 |
2024-02-08 |
BioNTech SE |
Nucleic acid compositions containing amphiphilic oligoethylene glycol (OEG) conjugated compounds and methods of using such compounds and compositions
|
|
WO2024027910A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
CN114989027B
(zh)
*
|
2022-08-03 |
2023-01-31 |
深圳市瑞吉生物科技有限公司 |
用于递送核酸的阳离子脂质化合物和组合物及用途
|
|
CN119968210A
(zh)
|
2022-08-03 |
2025-05-09 |
生物技术公司 |
用于预防或治疗结核病的rna
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024032753A1
(zh)
*
|
2022-08-12 |
2024-02-15 |
上海蓝鹊生物医药有限公司 |
含氮链状化合物、其制备方法、包含其的组合物和应用
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
IL318767A
(en)
|
2022-08-19 |
2025-04-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for regulating hepatitis B virus through targeted gene repression
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
CN115557875B
(zh)
*
|
2022-08-19 |
2025-01-03 |
上海耐澄生物科技有限公司 |
一种脂质化合物及脂质纳米颗粒
|
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
CA3265596A1
(en)
|
2022-08-31 |
2024-03-07 |
Sail Biomedicines, Inc. |
NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES, AS WELL AS ASSOCIATED METHODS OF USE
|
|
WO2024051825A1
(zh)
|
2022-09-09 |
2024-03-14 |
厦门赛诺邦格生物科技股份有限公司 |
一种碳核阳离子脂质
|
|
EP4587166A1
(en)
|
2022-09-15 |
2025-07-23 |
Pfizer Inc. |
Coaxial flow device for nanoparticle preparation and manufacturing equipment including such device
|
|
WO2024057237A1
(en)
|
2022-09-16 |
2024-03-21 |
Pfizer Inc. |
Lipid nanoparticles
|
|
EP4582409A1
(en)
*
|
2022-09-19 |
2025-07-09 |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Method for preparing 2-hydroxyethyl aminocaproate compound and use thereof
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
IL319414A
(en)
|
2022-09-23 |
2025-05-01 |
BioNTech SE |
Compositions for delivering antigens at the liver level and related methods
|
|
CN120152736A
(zh)
|
2022-09-23 |
2025-06-13 |
生物技术欧洲股份公司 |
用于递送疟原虫csp抗原的组合物及相关方法
|
|
CN119947747A
(zh)
|
2022-09-26 |
2025-05-06 |
葛兰素史克生物有限公司 |
流感病毒疫苗
|
|
EP4598946A1
(en)
|
2022-10-05 |
2025-08-13 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
JP2025534447A
(ja)
|
2022-10-06 |
2025-10-15 |
バイオエヌテック エスエー |
クローディン１８．２を標的とするｒｎａ組成物
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
CN120153078A
(zh)
|
2022-10-27 |
2025-06-13 |
辉瑞大药厂 |
编码rsv-f的rna分子及含所述rna分子的疫苗
|
|
WO2024089634A1
(en)
|
2022-10-27 |
2024-05-02 |
Pfizer Inc. |
Immunogenic compositions against influenza and rsv
|
|
WO2024089229A1
(en)
|
2022-10-28 |
2024-05-02 |
CureVac SE |
Improved formulations comprising lipid-based carriers encapsulating rna
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
WO2024097664A1
(en)
|
2022-10-31 |
2024-05-10 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
CN115417778B
(zh)
*
|
2022-11-01 |
2023-06-20 |
北京华芢生物技术有限公司 |
可离子化的阳离子脂c5及由其组成的纳米脂质体颗粒
|
|
CN115433099B
(zh)
*
|
2022-11-03 |
2023-06-16 |
北京华芢生物技术有限公司 |
可离子化的阳离子脂c6及由其组成的纳米脂质体颗粒
|
|
JP2025538939A
(ja)
|
2022-11-04 |
2025-12-03 |
ファイザー・インク |
脂質化合物およびその使用
|
|
WO2024094211A1
(zh)
*
|
2022-11-06 |
2024-05-10 |
斯微(上海)生物科技股份有限公司 |
一种脂质组合物
|
|
EP4615465A1
(en)
|
2022-11-08 |
2025-09-17 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for producing circular polyribonucleotides
|
|
JP2025537178A
(ja)
|
2022-11-08 |
2025-11-14 |
オーナ セラピューティクス， インコーポレイテッド |
環状ｒｎａ組成物
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
CN120265279A
(zh)
|
2022-11-21 |
2025-07-04 |
翻译生物公司 |
信使rna的干粉配制品的组合物及其使用方法
|
|
AU2023383821A1
(en)
|
2022-11-24 |
2025-05-29 |
Themedium Therapeutics Co., Ltd |
Novel lipids used for nucleic acid delivery and lipid nanoparticle composition
|
|
AU2023406303A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
AU2023406321A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
CN120615013A
(zh)
|
2022-12-01 |
2025-09-09 |
世代生物公司 |
用于细胞靶向的隐形脂质纳米颗粒组合物
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
WO2024123633A1
(en)
|
2022-12-08 |
2024-06-13 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2024121814A1
(en)
|
2022-12-09 |
2024-06-13 |
Takeda Pharmaceutical Company Limited |
Modified immunomodulators
|
|
EP4630049A1
(en)
|
2022-12-11 |
2025-10-15 |
Pfizer Inc. |
Immunogenic compositions against influenza and rsv
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
CN120344258A
(zh)
|
2022-12-15 |
2025-07-18 |
赛诺菲巴斯德有限公司 |
编码流感病毒样颗粒的mRNA
|
|
JP2026501211A
(ja)
|
2022-12-19 |
2026-01-14 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Ｂ型肝炎組成物
|
|
AU2023408413A1
(en)
|
2022-12-19 |
2025-05-08 |
Green Cross Corporation |
Cycloalkane-based lipid compound for delivering nucleic acids, and lipid nanoparticles comprising same
|
|
TW202438514A
(zh)
|
2022-12-20 |
2024-10-01 |
法商賽諾菲公司 |
鼻病毒mrna疫苗
|
|
CN119095585A
(zh)
*
|
2022-12-21 |
2024-12-06 |
苏州艾博生物科技有限公司 |
包含固醇修饰的磷脂的脂质纳米颗粒
|
|
EP4637717A1
(en)
|
2022-12-23 |
2025-10-29 |
Pfizer Inc. |
Lipid particle compositions and methods of use thereof
|
|
CN121127490A
(zh)
|
2022-12-28 |
2025-12-12 |
生物技术欧洲股份公司 |
靶向hiv的rna组合物
|
|
IL321761A
(en)
*
|
2022-12-28 |
2025-08-01 |
Astellas Pharma Inc |
4-aminopiperidine compound, lipid nanoparticles thereof, and pharmaceutical composition containing same
|
|
AU2023414262B2
(en)
|
2022-12-29 |
2025-08-14 |
Rinuagene Biotechnology Co., Ltd. |
Polynucleotide molecule for preventing or treating hpv infection-related diseases
|
|
CN120435314A
(zh)
|
2022-12-29 |
2025-08-05 |
波普瓦克斯私人有限公司 |
多靶疫苗和治疗剂
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
CN116178193B
(zh)
|
2023-01-05 |
2023-07-28 |
北京悦康科创医药科技股份有限公司 |
高效低毒且稳定性表达的阳离子脂质化合物及其组合物
|
|
CN115745820B
(zh)
*
|
2023-01-05 |
2023-04-28 |
北京悦康科创医药科技股份有限公司 |
长效低毒的新型阳离子脂质化合物及其组合物
|
|
CN115677518B
(zh)
*
|
2023-01-05 |
2023-04-14 |
北京悦康科创医药科技股份有限公司 |
用于递送核酸的可电离阳离子脂质化合物和组合物及用途
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
US20240238473A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024151685A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
EP4648793A1
(en)
|
2023-01-11 |
2025-11-19 |
ModernaTX, Inc. |
Personalized cancer vaccines
|
|
EP4651890A1
(en)
|
2023-01-16 |
2025-11-26 |
Pfizer Inc. |
Immunogenic compositions and methods of inducing an immune response against varicella zoster virus
|
|
WO2024153324A1
(en)
|
2023-01-18 |
2024-07-25 |
BioNTech SE |
Rna formulations for pharmaceutical use
|
|
KR20250153793A
(ko)
|
2023-01-27 |
2025-10-27 |
세일 바이오메디슨스, 인크. |
변형된 지질 조성물 및 이의 용도
|
|
WO2024161249A1
(en)
|
2023-01-31 |
2024-08-08 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
WO2024165146A1
(en)
|
2023-02-07 |
2024-08-15 |
Biontech Cell & Gene Therapies Gmbh |
Immune effector cells stably and transiently expressing nucleic acids
|
|
CN115784921B
(zh)
|
2023-02-08 |
2023-05-05 |
北京悦康科创医药科技股份有限公司 |
肝外靶向高效低毒的阳离子脂质化合物及其组合物
|
|
US20240293318A1
(en)
|
2023-02-13 |
2024-09-05 |
Flagship Pioneering Innovations Vii, Llc |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
AU2024220221A1
(en)
|
2023-02-17 |
2025-08-07 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
TW202438089A
(zh)
|
2023-02-17 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
包含經修飾的尿嘧啶的ｄｎａ組成物
|
|
WO2024178305A1
(en)
|
2023-02-24 |
2024-08-29 |
Modernatx, Inc. |
Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
|
|
WO2024180363A1
(en)
|
2023-02-28 |
2024-09-06 |
BioNTech SE |
Linker sequence potency assays for multiple coding nucleic acids
|
|
CN121002196A
(zh)
|
2023-02-28 |
2025-11-21 |
百欧恩泰欧洲股份公司 |
用于多种编码核酸的接头序列效力测定
|
|
DE112024001143T5
(de)
|
2023-03-08 |
2025-12-18 |
CureVac SE |
Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
|
|
IL322837A
(en)
|
2023-03-09 |
2025-10-01 |
BioNTech SE |
Peptidoglycan hydrolases with bactericidal activity
|
|
WO2024192291A1
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
WO2024192420A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
EP4680595A2
(en)
|
2023-03-15 |
2026-01-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2024194767A1
(en)
|
2023-03-17 |
2024-09-26 |
BioNTech SE |
Automated drug production system
|
|
CN118666726A
(zh)
*
|
2023-03-17 |
2024-09-20 |
尧唐(上海)生物科技有限公司 |
递送治疗剂的脂质化合物及其制备方法与应用
|
|
WO2024193827A1
(en)
|
2023-03-23 |
2024-09-26 |
BioNTech SE |
Stabilized nucleic acid compositions and methods for preparing, storing and using the same
|
|
TW202444921A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向lpa之組合物及方法
|
|
WO2024206555A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
TW202444914A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
抑制子融合蛋白系統
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024200826A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
|
|
WO2024206835A1
(en)
|
2023-03-30 |
2024-10-03 |
Modernatx, Inc. |
Circular mrna and production thereof
|
|
WO2024200823A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
AR132276A1
(es)
|
2023-04-07 |
2025-06-11 |
Takeda Pharmaceuticals Co |
Complejo de conjugación
|
|
WO2024209418A1
(en)
|
2023-04-07 |
2024-10-10 |
BioNTech SE |
Heating and cooling jacket for fluid vessels
|
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
WO2024216191A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
WO2024216212A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2024213776A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
CN121398842A
(zh)
|
2023-04-14 |
2026-01-23 |
百欧恩泰欧洲股份公司 |
用于预防或治疗结核病的rna
|
|
KR20250169566A
(ko)
|
2023-04-14 |
2025-12-03 |
바이오엔테크 에스이 |
Hiv 백신
|
|
AU2024256347A1
(en)
|
2023-04-17 |
2025-11-27 |
Sanofi Pasteur Inc. |
Reconstitutable dry powder formulations and methods of use thereof
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
CN117384055B
(zh)
*
|
2023-04-27 |
2024-11-19 |
仁景(苏州)生物科技有限公司 |
用于递送治疗剂的可电离脂质及其用途
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
CN121038807A
(zh)
|
2023-05-03 |
2025-11-28 |
生物技术欧洲股份公司 |
优化的csp变体及相关方法
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024236504A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Sequences and methods for delivery of dna and rna
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024236361A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for delivery of nucleic acids to cells
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
TW202516017A
(zh)
|
2023-06-14 |
2025-04-16 |
美商輝瑞股份有限公司 |
多核苷酸組成物及其用途
|
|
CN119143620A
(zh)
*
|
2023-06-16 |
2024-12-17 |
北京剂泰医药科技有限公司 |
一种快速代谢的脂质化合物
|
|
WO2024260570A1
(en)
|
2023-06-23 |
2024-12-26 |
CureVac SE |
Nucleic acid encoded antibodies
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025003760A1
(en)
|
2023-06-28 |
2025-01-02 |
Sanofi |
Sterol analogs in lipid nanoparticle formulations
|
|
WO2025003406A1
(en)
|
2023-06-29 |
2025-01-02 |
BioNTech SE |
Modular multiplatform system for mrna drug production
|
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2025006385A1
(en)
|
2023-06-30 |
2025-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel malaria vaccine comprising ama1 and ron2 antigens
|
|
TW202516012A
(zh)
*
|
2023-06-30 |
2025-04-16 |
大陸商深圳深信生物科技有限公司 |
水痘帶狀皰疹病毒（ｖｚｖ）疫苗
|
|
US20250135006A1
(en)
|
2023-07-07 |
2025-05-01 |
Pfizer Inc. |
Amphiphilic tlr7/8 adjuvants and uses thereof
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
WO2025017476A1
(en)
|
2023-07-19 |
2025-01-23 |
Pfizer Inc. |
Lipid nanoparticles comprising polymer-conjugated lipids and uses thereof
|
|
WO2025021277A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Agents and methods for targeted delivery of cytokines to immune cells
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
US20250092426A1
(en)
|
2023-07-25 |
2025-03-20 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025027116A1
(en)
|
2023-08-01 |
2025-02-06 |
Institut Curie |
Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
|
|
WO2025026553A1
(en)
|
2023-08-02 |
2025-02-06 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025036992A1
(en)
|
2023-08-16 |
2025-02-20 |
CureVac SE |
Rna conjugates
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025054236A2
(en)
*
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025051994A1
(en)
|
2023-09-07 |
2025-03-13 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
TW202540154A
(zh)
|
2023-09-11 |
2025-10-16 |
德商拜恩技術股份公司 |
用於遞送腸促胰島素劑之ｒｎａ組合物
|
|
CN119591513A
(zh)
*
|
2023-09-11 |
2025-03-11 |
苏州星核迪赛生物技术有限公司 |
局部递送药物的材料及其应用
|
|
WO2025057115A2
(en)
|
2023-09-15 |
2025-03-20 |
Pfizer Inc. |
Methods and compositions for continuous production of nucleic acids
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025061863A1
(en)
|
2023-09-20 |
2025-03-27 |
BioNTech SE |
Method
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
CN119330848B
(zh)
*
|
2023-10-19 |
2025-07-08 |
仁景(苏州)生物科技有限公司 |
用于递送的脂质化合物及脂质纳米颗粒
|
|
WO2025088088A1
(en)
|
2023-10-27 |
2025-05-01 |
CureVac SE |
Rna composition for improving cell therapy
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025093665A1
(en)
|
2023-10-31 |
2025-05-08 |
BioNTech SE |
Particles, compositions and methods
|
|
CN118147134B
(zh)
|
2023-11-06 |
2025-02-25 |
北京悦康科创医药科技股份有限公司 |
靶向调控PCSK9基因表达的siRNA及其应用
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
CN117550985B
(zh)
*
|
2023-11-08 |
2025-02-18 |
深圳厚存纳米药业有限公司 |
一种脂质化合物及其用途
|
|
WO2025103803A1
(en)
|
2023-11-13 |
2025-05-22 |
CureVac SE |
Immunotherapy against neuronal and brain tumors
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
DE102024133412A1
(de)
|
2023-11-15 |
2025-05-15 |
BioNTech SE |
Sars-cov-2 immunogene zusammensetzungen
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
US20250161227A1
(en)
|
2023-11-17 |
2025-05-22 |
Acuitas Therapeutics, Inc. |
Pegylated lipids
|
|
WO2025106915A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
|
|
WO2025106930A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
|
|
WO2025111526A1
(en)
|
2023-11-22 |
2025-05-30 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
EP4559898A1
(en)
|
2023-11-24 |
2025-05-28 |
AldexChem Kft. |
Novel ionizable cationic lipids containing thioether linkage
|
|
WO2025114520A1
(en)
|
2023-12-01 |
2025-06-05 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
US20250188016A1
(en)
|
2023-12-12 |
2025-06-12 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025126019A1
(en)
|
2023-12-13 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025132122A1
(en)
|
2023-12-13 |
2025-06-26 |
Berlin Institute Of Health |
Methods of delivering therapeutics using lipid nanoparticles
|
|
WO2025126071A1
(en)
|
2023-12-14 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025126113A1
(en)
|
2023-12-15 |
2025-06-19 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
WO2025126118A1
(en)
|
2023-12-15 |
2025-06-19 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025133115A1
(en)
|
2023-12-21 |
2025-06-26 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising il-35
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025134046A1
(en)
|
2023-12-22 |
2025-06-26 |
Pfizer Inc. |
Methods and vaccine compositions for lyme disease
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
CN117820149B
(zh)
*
|
2023-12-29 |
2025-01-07 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025166323A2
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting lipoprotein (a) expression
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025174858A1
(en)
|
2024-02-15 |
2025-08-21 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025186719A1
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2025186725A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Improved lnp formulations and uses thereof
|
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
WO2025202834A1
(en)
|
2024-03-26 |
2025-10-02 |
Pfizer Inc. |
Polynucleotide compositions and uses thereof
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
CN118255678B
(zh)
*
|
2024-03-28 |
2024-12-24 |
荣灿生物医药技术(上海)有限公司 |
一种可电离脂质化合物及其应用
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025210521A1
(en)
|
2024-04-04 |
2025-10-09 |
Genevant Sciences Gmbh |
Lipid nanoparticles for stimulating t cells
|
|
WO2025210520A1
(en)
|
2024-04-04 |
2025-10-09 |
Genevant Sciences Gmbh |
Lipid nanoparticles for inducing an immunological response
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217131A1
(en)
*
|
2024-04-08 |
2025-10-16 |
Popvax Private Limited |
Novel lipids for delivery of nucleic acid therapeutics
|
|
WO2025217264A1
(en)
|
2024-04-10 |
2025-10-16 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
CN118319880B
(zh)
*
|
2024-04-15 |
2025-02-07 |
荣灿生物医药技术(上海)有限公司 |
靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
|
|
WO2025224684A1
(en)
|
2024-04-24 |
2025-10-30 |
BioNTech SE |
Compositions and methods for producing engineered immune cells
|
|
WO2025228975A1
(en)
|
2024-04-29 |
2025-11-06 |
BioNTech SE |
Particles, compositions and methods
|
|
WO2025231114A1
(en)
|
2024-05-01 |
2025-11-06 |
Acuitas Therapeutics, Inc. |
Method of using lipid nanoparticles for intramuscular delivery
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240833A1
(en)
|
2024-05-17 |
2025-11-20 |
Acuitas Therapeutics, Inc. |
Galnac lipid compounds for use in lipid nanoparticles
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025238563A1
(en)
|
2024-05-17 |
2025-11-20 |
Pfizer Inc. |
Coaxial mixing device for nanoparticle preparation and manufacturing equipment including such mixing device
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025242815A1
(en)
|
2024-05-23 |
2025-11-27 |
CureVac SE |
Immunotherapy of squamous cell carcinoma
|
|
CN118240844B
(zh)
|
2024-05-27 |
2024-12-13 |
北京悦康科创医药科技股份有限公司 |
带状疱疹mRNA疫苗及其制备方法和应用
|
|
WO2025250751A1
(en)
|
2024-05-31 |
2025-12-04 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2025264662A1
(en)
|
2024-06-18 |
2025-12-26 |
BioNTech SE |
Compositions and methods for treatment of melanoma
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
AU2025205193A1
(en)
|
2024-07-08 |
2026-01-29 |
Hangzhou Tianlong Pharmaceutical Co., Ltd. |
Double-Stranded RNAi Agents For Targeting And Regulating HBV Gene Expression, And A Use Thereof
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
US20260021175A1
(en)
|
2024-07-17 |
2026-01-22 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026021698A1
(en)
|
2024-07-23 |
2026-01-29 |
BioNTech SE |
Nucleic acid particle
|
|
CN119930462B
(zh)
*
|
2025-04-08 |
2025-06-27 |
北京悦康科创医药科技股份有限公司 |
基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途
|